Research and Markets: Pliva-Lachema Gains FDA Approval for Sterile Dosage Manufacturing.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c44030) has announced the addition of the latest report from Espicom Business Intelligence Introduction Espicom Business Intelligence is a publisher of independent and impartial information and analysis services focusing on the pharmaceutical and medical device markets. Ltd. "Pliva Generics Company Intelligence Report" to their offering. These generics company reports will help you to understand the dynamic and complex issues affecting the business of leading generic industry players. These informative reports provide an insight into the company, covering the structure of the business, the most recent quarterly and annual financial results, information on the company's active product lines and ANDA ANDA abbr. abbreviated new drug application approvals, along with a review of major developments, such as M&A activity, strategic alliances, and litigation An action brought in court to enforce a particular right. The act or process of bringing a lawsuit in and of itself; a judicial contest; any dispute. When a person begins a civil lawsuit, the person enters into a process called litigation. . The easy and cost effective way to monitor developments in leading generic drug generic drug, a drug sold or prescribed under the nonproprietary name of its active ingredients or under a generally descriptive name rather than under a brand or trade name. industry players. Generics Company Reports are packed with facts, figures and statistics, providing you with the most thorough ongoing monitoring of the important generic companies. From financial performance to litigation, no other service provides such comprehensive insight to the companies driving growth in this rapidly expanding area of the pharmaceutical industry. Each report is updated and issued every quarter. This ongoing monitoring and regular delivery ensures that developments are incorporated into the relevant reports. This vigilance ensures that whether it's the latest deals, ANDAs, alliances or litigation you can assess the impact of the development in the context of the company, its competitors and the broader market. Use Generic Company Reports to: -- Evaluate the competitive operating environment. -- Identify which companies are applying for ANDAs, and for what. -- Understand generic companies' product line up. -- Monitor the financial performance of leading generics players. -- Track the twists and turns of litigation. Stay in touch with the latest M&A and strategic alliances Key Topics Covered Include: -- Strategic review, more focus on generics -- Pliva-Lachema gains FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. approval for sterile dosage manufacturing -- Financial Results -- Latest Full Year Results Revenues by Segment, 2003-04 -- Geographic Segment Data -- Pharmaceutical Sales by Region, 2003-04 -- Latest Quarter Results, third quarter ended 30th September 2005 -- Major Developments -- Mergers, acquisitions and agreements Products Mentioned Include: -- Sertraline sertraline /ser·tra·line/ (ser´trah-len) a selective serotonin reuptake inhibitor used as the hydrochloride salt in the treatment of depression, obsessive-compulsive disorder, and panic disorder. (tentative) -- Azithromycin -- Citalopram hydrobromide ci·tal·o·pram hy·dro·bro·mide n. A drug of the SSRI class that is used primarily to treat depression. Citalopram hydrobromide Celexa; a SSRI that is highly specific for serotonin reuptake. -- Zolpidem tartrate zol·pi·dem tartrate n. A nonbenzodiazepine hypnotic drug used to treat insomnia. zolpidem tartrate Ambien, Ambien CR, Stilnoct (UK), Tovalt ODT Pharmacologic class: Imidazopyridine (tentative) -- Propafenone For more information visit http://www.researchandmarkets.com/reports/c44030 |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion